Brentuximab Vedotin Active, Well-tolerated in Cutaneous T-Cell Lymphoma
For the open-label phase II study, researchers enrolled 48 patients with CD30+ lymphoproliferative disorders or mycosis fungoides. All patients received brentuximab vedotin 1.8 mg/kg intravenously every 21 days. Results showed an overall response rate ...
Cancer Therapy Advisor - Tue, 11 Aug 2015 09:00

Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders
Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) from healthy donors led to high response rates and significant extensions in overall survival (OS) for patients with rituximab-refractory EBV–associated lymphoproliferative ...
OncLive - Sun, 19 Apr 2015 06:10

The Epstein-Barr Virus, Magnesium and ME/CFS Connection (?)
EBV infections don't necessarily lead to or are even associated with these problems: only one type of EBV patient was shown to have them in this study. People with chronic active EBV infections (CAEBV) or something called X-linked lymphoproliferative ...
ProHealth - Sun, 30 Aug 2015 00:07

Prognostic signature and clonality pattern of recurrently mutated genes in ...
We applied a high-throughput deep-targeted analysis, especially designed for covering widely TP53 and ATM genes, in 180 patients with inactive disease at diagnosis, to test the independent prognostic value of CLL somatic recurrent mutations. ... CD22 ... - Fri, 28 Aug 2015 06:18

Non-Hodgkin Lymphoma of the Stomach in a Patient Treated With Natalizumab
Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use.
Cancer Therapy Advisor - Mon, 10 Aug 2015 06:27

New guidelines address primary cutaneous T-cell lymphoproliferative disorders
HOLLYWOOD, FLA. – The treatment of patients with lymphomatoid papulosis depends on the presentation, according to new National Comprehensive Cancer Network guidelines for managing primary cutaneous CD30+ T-cell lymphoproliferative disorders.
The Oncology Report - Wed, 16 Apr 2014 13:19

Higher Rates of Lymphoproliferative Disorders in Patients with Celiac Disease
A team of researchers recently investigated rates of various lymphoproliferative disorders in patients with celiac disease. The research team included L.A. Leslie, B. Lebwohl, A.I. Neugut, J. Gregory Mears, G. Bhagat, and P.H. Green. They are ... - Mon, 30 Jul 2012 00:18

VISA - Vector Integration Site Analysis server: a web-based server to rapidly ...
Retroviral vector mediated gene therapy has enormous potential for treating genetic disorders [1] and infectious diseases [2]. Unfortunately, vector integration can lead to the dysregulation of nearby genes, commonly referred to as genotoxicity [3 ...
BMC Blogs Network - Mon, 06 Jul 2015 06:48

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014